The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients: authors' response

regarding the infl uence of anti-cyclic citrullinated peptide (CCP) on anticentromere antibody (ACA)-positive patients suff er ing from rheumatoid arthritis (RA) [1]. Th eir fi ndings explore the eff ect of ACA positivity in a patient group diff erent from the cohort of primary Sjögren syndrome (SS) patients we chose to study [2]. Due to the diff erent study population and the retrospective nature of our work, our data do not include measurement of anti-CCP antibodies. Anti-CCP anti-bodies provide a specifi c tool for the diagnosis of RA that seems to correlate with disease severity and early erosive disease. Th e method has a 70% sensitivity for RA [3], which is consistent with the 70.6% positivity of anti-CCP reported by Jearn and Kim among their ACA-positive RA group. A striking point in the results presented by the two colleagues is the high prevalence (21%) of RA among ACA-positive patients, which is not in line with previous publications that have reported a prevalence of 5 to 6% [4]. In a general population of RA patients with variable antibody background, interstitial lung disease and Raynaud's phenomenon have a reported prevalence in the range of 7.7 to 10% [5]. Jearn and Kim found 4 (11.8%) patients with interstitial lung disease and 1 (10%) patient with Raynaud's phenomenon out of 34 ACA-positive RA patients. Despite the fact that the numbers are small and do not allow for safe conclusions, both results are well in the range reported in the literature for unselected RA patients and unrelated to the anti-CCP positivity. Th is could, in a sense, indicate that the presence of ACA or anti-CCP antibodies in RA does not aff ect the clinical features in question. We believe that an extended presentation of the results found by Jearn and Kim would be very interesting and more than welcome. We also think that evaluation of our ACA-positive SS patients for anti-CCP reactivity should be interesting. References 1. Jearn L-H, Kim T-Y: The infl uence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients. Anticentromere antibody positive Sjögren's syndrome: a retrospective descriptive analysis. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Cite this article as: Vlachotiannopoulos PG, Bournia V-K: The infl uence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients: authors' response.